In Vitro Diagnostic Quality Control Market By: Product (Quality Control Products, Serum/Plasma-Based Controls, Whole Blood-Based Controls, Urine-Based Controls, Other Source-Based IVD Quality Controls, Data Management Solutions, and Quality Assurance Services), Manufacturer (Third Party Controls, Independent Controls, Instrument-Specific Control and Original Equipment Manufacturer Controls), Application (Clinical chemistry, Immunochemistry, Hematology, Coagulation & Hemostasis, Microbiology, Molecular Diagnostics and Other Applications), End-User (Hospitals, Clinical Laboratories, Academic & Research Institutes, and Other End Users), Geography (North America, Europe, APAC, and RoW)– Forecast up to 2026
- Report Code : IHR2138709
- Published On: Apr, 2021
- Category : Diagnostics
- Pages : 86
-
In Vitro Diagnostic is the test done on the blood or tissue samples taken from the body. The in vitro diagnostic quality controls are samples used to check the reliability of the in vitro diagnostic testing system to validate the accuracy of the test results. These quality controls also evaluate the impact of the various factors including environmental conditions and operator’s performance on test results. As a result of this the In Vitro Diagnostic Quality Control market is attributed to control the accuracy of the test laboratories, clinical laboratories and pathology labs where the tests are done.
The in-vitro diagnostic quality control market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology, along with an irreplaceable blend of primary insights. The real-time assessment of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary participants have helped in compiling relevant aspects with realistic parametric estimations for a comprehensive study. The participation share of different categories of primary participants is given below:
The rise in these accredited clinical laboratories is driving the market growth. Further, the adoption of the third-party quality controls, rapid increase in the chronic and infectious diseases are other major drivers for the market. The increase in demand of multi analyte controls gives the opportunity the vendors to fulfil the end-user demand. The In Vitro Diagnostic Quality Control Market is expected to reach USD 1,220 million by 2026 from an estimated value of USD 999.44 million in 2020, growing at a CAGR of ~3.38% during the forecast period.
The In Vitro Diagnostic Quality Control market has segmented based on product and service, manufacturer, application, end user and region.
Product based segmentation:
• Quality Control Products
• Serum/Plasma-Based Controls
• Whole Blood-Based Controls
• Urine-Based Controls
• Other Controls
• Quality Assurance Services
• Data Management Solutions
Manufacturer based segmentation:
• Third-Party Controls
• Independent Controls
• Instrument-Specific Controls
• Original Equipment Manufacturer Controls
Application based segmentation:
• Clinical chemistry
• Immunochemistry
• Hematology
• Coagulation & Hemostasis
• Microbiology
• Molecular Diagnostics
• Other Applications
End-User based segmentation:
• Hospitals
• Clinical Laboratories
• Academic and Research Institutes
• Other End Users
Region based segmentation:
• North America
• Europe
• APAC
• RoW
In the application segmentation immunochemistry plays a major role in the growth of the market. The demand for this segment is attributed to the increased utilization of the multi-analyte controls to perform immunoassay tests in the labs. Thus, the immunochemistry has been taking the largest market share in the forecast period.
In product and services segment the Quality Assurance Services market growing at a highest growth rate due to increasing need of performance assessment in clinical laboratories. The quality control products segment accounted largest market share in In Vitro Diagnostic Quality Control market due to increasing demand for serum/plasma-based controls for stability and accuracy of test result.
Further, the market segmentation is based on manufacturer - it is divided into third party controls and original equipment manufacturer controls. The third-party controls segment accounted largest share in the market due to the unbiased test results. This results in the high rise in the demand of the third-party controls products in the market.
Based on the end-users the market is divided into hospitals, academic and research institutes and other end-users. The hospitals have the prominent role in the in vitro diagnostic quality control growth rate due to the increasing amount of IVD procedures in the hospitals. Clinical laboratories are also expected to increase the demand for In Vitro Diagnostic Quality Control products.
As per the regional analysis, North America has the largest share in the global In Vitro Diagnostic Quality Control due to the factors such as increasing IVD procedures, growing awareness of the ensured and accurate test results, in addition to these the increased adoption of the third-party controls also fuel the demand for In Vitro Diagnostic Quality Control products and services.
Globally the In Vitro Diagnostic Quality Control market has been expanding its growth – the factors which are driving this market are the increasing awareness of the ensured and accurate test results, scenario of the increased chronic and infectious diseases where the accurate test is needed to cure, treat and prevent the disease. The rise in the demand of the multi-analyte controls gives the opportunity to the in vitro diagnostic quality control.
The high cost of the quality control process hinders the demand for In Vitro Diagnostic Quality products and services. Strict rules for product approval procedure and the lack of regulations for clinical laboratory accreditation in developing countries are major challenges in the market.
The key competitors in the In Vitro Diagnostic Quality market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Technopath Clinical Diagnostics, Randox Laboratories Ltd., Bio-Techne Corporation, Danaher Corporation, SeraCare Life Sciences Inc., Roche Diagnostics, Sysmex Corporation, Fortress Diagnostics, Helena Laboratories, Siemens Healthineers, Abbott Laboratories Inc., Helena Laboratories, and Diagnostics, Inc.
This report analysis helps the vendors in the market to know the current trends, dynamics and opportunities of the market and needs of the end-users. The qualitative and quantitative analysis enhances the user experience of the report.
● The competitive analysis of the major players enables users to understand the dynamic strategies such as product innovation, partnerships, merger & acquisitions and joint ventures of the key players
● This report also provides the SWOT analysis, portfolio analysis, capability analysis of the leading players
● The report will also help the research organization of In Vitro Diagnostic Quality to support their development activities
● Quantitative analysis of the market enables users to understand the actual facts of the market across four major regions
-
With tables and figures helping analyze worldwide In Vitro Diagnostic Quality Control market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
1. Executive Summary
2. Industry Outlook
2.1. Industry Overview
2.2. Industry Trends
3. Market Snapshot
3.1. Market Definition
3.2. Market Outlook
3.3. PEST Analysis
3.4. Porter Five Forces
3.5. Related Markets
4. Market characteristics
4.1. Market Evolution
4.2. Market Trends and Impact
4.3. Advantages/Disadvantages of Market
4.4. Regulatory Impact
4.5. Market Offerings
4.6. Market Segmentation
4.7. Market Dynamics
4.7.1. Drivers
4.7.2. Restraints
4.7.3. Opportunities
4.8. DRO - Impact Analysis
5. Product: Market Size & Analysis
5.1. Overview
5.2. Quality Control Products
5.3. Serum/Plasma-Based Controls
5.4. Whole Blood-Based Controls
5.5. Urine-Based Controls
5.6. Other Source-Based IVD Quality Controls
5.7. Data Management Solutions
5.8. Quality Assurance Services
6. Application: Market Size & Analysis
6.1. Overview
6.2. Immunochemistry/Immunoassay
6.3. Clinical Chemistry
6.4. Hematology
6.5. Molecular Diagnostics
6.6. Coagulation & Hemostasis
6.7. Microbiology
6.8. Other Applications
7. Manufacturer: Market Size & Analysis
7.1. Overview
7.2. Third-Party Control Manufacturers
7.3. Independent Controls
7.4. Instrument-Specific Controls
7.5. Original Equipment Manufacturers
8. End User: Market Size & Analysis
8.1. Overview
8.2. Hospitals
8.3. Clinical Laboratories
8.4. Academic & Research Institutes
8.5. Other End Users
9. Geography: Market Size & Analysis
9.1. Overview
9.2. North America
9.3. Europe
9.4. Asia Pacific
9.5. Rest of the World
10. Competitive Landscape
10.1. Competitor Comparison Analysis
10.2. Market Developments
10.3. Mergers and Acquisitions, Legal, Awards, Partnerships
10.4. Product Launches and execution
11. Vendor Profiles
11.1. Sun Diagnostics
11.1.1. Overview
11.1.2. Product Offerings
11.1.3. Geographic Revenue
11.1.4. Business Units
11.1.5. Developments
11.1.6. SWOT Analysis
11.1.7. Business Strategy
11.2. Quidel Corporation
11.2.1. Overview
11.2.2. Product Offerings
11.2.3. Geographic Revenue
11.2.4. Business Units
11.2.5. Developments
11.2.6. SWOT Analysis
11.2.7. Business Strategy
11.3. Technopath Clinical Diagnostics
11.3.1. Overview
11.3.2. Product Offerings
11.3.3. Geographic Revenue
11.3.4. Business Units
11.3.5. Developments
11.3.6. SWOT Analysis
11.3.7. Business Strategy
11.4. Danaher Corporation
11.4.1. Overview
11.4.2. Product Offerings
11.4.3. Geographic Revenue
11.4.4. Business Units
11.4.5. Developments
11.4.6. SWOT Analysis
11.4.7. Business Strategy
11.5. Abbott Laboratories Inc
11.5.1. Overview
11.5.2. Product Offerings
11.5.3. Geographic Revenue
11.5.4. Business Units
11.5.5. Developments
11.5.6. SWOT Analysis
11.5.7. Business Strategy
11.6. Sysmex Corporation
11.6.1. Overview
11.6.2. Product Offerings
11.6.3. Geographic Revenue
11.6.4. Business Units
11.6.5. Developments
11.6.6. SWOT Analysis
11.6.7. Business Strategy
11.7. Siemens Healthineers
11.7.1. Overview
11.7.2. Product Offerings
11.7.3. Geographic Revenue
11.7.4. Business Units
11.7.5. Developments
11.7.6. SWOT Analysis
11.7.7. Business Strategy
11.8. Fortress Diagnostics
11.8.1. Overview
11.8.2. Product Offerings
11.8.3. Geographic Revenue
11.8.4. Business Units
11.8.5. Developments
11.8.6. SWOT Analysis
11.8.7. Business Strategy
11.9. Zeptometrix Corporation
11.9.1. Overview
11.9.2. Product Offerings
11.9.3. Geographic Revenue
11.9.4. Business Units
11.9.5. Developments
11.9.6. SWOT Analysis
11.9.7. Business Strategy
11.10. Qnostics
11.10.1. Overview
11.10.2. Product Offerings
11.10.3. Geographic Revenue
11.10.4. Business Units
11.10.5. Developments
11.10.6. SWOT Analysis
11.10.7. Business Strategy
12. Companies to Watch
12.1. Bio-Techne Corporation
12.1.1. Overview
12.1.2. Market
12.1.3. Business Strategy
12.2. Microbiologics
12.2.1. Overview
12.2.2. Market
12.2.3. Business Strategy
12.3. Bio-Rad Laboratories
12.3.1. Overview
12.3.2. Market
12.3.3. Business Strategy
12.4. Randox Laboratories
12.4.1. Overview
12.4.2. Market
12.4.3. Business Strategy
12.5. Thermo Fisher Scientific
12.5.1. Overview
12.5.2. Market
12.5.3. Business Strategy
12.6. Roche Diagnostics
12.6.1. Overview
12.6.2. Market
12.6.3. Business Strategy
12.7. Helena Laboratories
12.7.1. Overview
12.7.2. Market
12.7.3. Business Strategy
12.8. SeraCare Life Sciences
12.8.1. Overview
12.8.2. Market
12.8.3. Business Strategy
12.9. SERO AS
12.9.1. Overview
12.9.2. Market
12.9.3. Business Strategy
12.10. Ortho Clinical Diagnostics
12.10.1. Overview
12.10.2. Market
12.10.3. Business Strategy
13. Analyst Opinion
14. Annexure
14.1. Report Scope
14.2. Market Definitions
14.3. Research Methodology
14.3.1. Data Collation and In-house Estimation
14.3.2. Market Triangulation
14.3.3. Forecasting
14.4. Report Assumptions
14.5. Declarations
14.6. Stakeholders
14.7. Abbreviations
-
The In Vitro Diagnostic Quality Control Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the In Vitro Diagnostic Quality Control Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
Depending upon the type of applications, the In Vitro Diagnostic Quality Control Market has been segmented into
From 2024 to 2029, the In Vitro Diagnostic Quality Control Market is expected to grow at a compound annual growth rate of YY%, reaching a value of USD XXX Million.
The value of the In Vitro Diagnostic Quality Control Market is estimated to be USD XXX million.
In this highly competitive and rapidly evolving In Vitro Diagnostic Quality Control Industry, top strategic priorities such as innovation, diversification, and M&A would remain consistent.
